Transforming medical devices for improved patient outcomes

PRECLINICAL STUDIES

Controlled and prolonged elution kinetics and
efficient drug
transfer to arteries

MiStent SES’s unique coating formulation and technology delivers a controlled and sustained release of a drug from a fully absorbable coating. Specifically, MiStent’s polymer disappears after 90 days, but the remaining crystalline drug particles continue to release active sirolimus, maintaining therapeutic levels in tissue up to nine months after stent implantation.

In a 30- and 90-day overlapped stent (OLS) comparison, MiStent has statistically significantly less inflammation than the bare-metal stent (BMS) at both time points. Additionally, at the 30-day mark, the overlap stent model showed significantly less neointimal thickness for MiStent compared to the Vision stent, with numerically less thickness (though not significantly less) seen after 60 days.

Read the publications related to this study:
Serial Evaluation of Vascular Response After Implantation of a New Sirolimus-Eluting Stent With Bioabsorbable Polymer (MISTENT®): An Optical Coherence Tomography and Histopathological Study

Enhanced Drug Delivery Capabilities from Stents Coated with Absorbable Polymer and Crystalline Drug